Have Researchers Just Found Another Cause of Parkinson’s Disease?

Health & LifestyleNews
486

Listen to article (english)

Translate to Spanish or other 102 languages!

New research suggests another potential biomarker and trigger for Parkinson’s disease. Image for illustration purposes
New research suggests another potential biomarker and trigger for Parkinson’s disease. Image for illustration purposes

Medical News Today

- Advertisement -
  • Researchers from the University of Copenhagen, in Denmark, have made an important breakthrough in our understanding of Parkinson’s disease.
  • Their discovery centres around the damage of mitochondrial DNA in brain cells and its potential as an early biomarker for the disease.
  • As this condition affects over 10 million individuals worldwide, these findings hold significant promise for the future of diagnostics and treatments.
  • With the implications of these damaged DNA pieces likened to an unchecked forest blaze, the research provides hope and a fresh direction in understanding and treating this condition.

Parkinson’s disease is a neurological condition that impacts movement. Initial symptoms involve shaking, diminished sense of smell and difficulties with coordination.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/have-researchers-just-found-another-cause-of-parkinsons-disease

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Inflammatory Breast Cancer
Next article
From Motherhood to EMT

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.
- Advertisement -